ADAM17 and COVID-19: COVID‐19 induces elevated levels of IL‐6 for at least 2 weeks after onset of the disease and besides IL‐6, molecules associated with IL‐6 pathway, such as ADAM metallopeptidase domain 17 (ADAM‐17), SARS‐CoV ssRNA, dual‐specificity phosphatase 1 (DUSP1) and p38 mitogen‐activated protein kinase (MAPK) have been suggested as therapeutic targets.54